ALK and non-small cell lung carcinoma: There are currently five ALK TKI approved by the US FDA for the treatment of advanced, ALK-altered NSCLC [Table 1]: crizotinib (first-generation), ceritinib, alectinib, brigatinib (second-generation), and lorlatinib (third-generation) [Figure 1][37-41].